Emma Qingbo Li Xu
Chairwoman/CEO
A&Z Pharmaceutical, Inc.
180 Oser Ave., Suite 300
Hauppauge , NY 11788-3709
United States
emmaerwin@azpharmaceutical.comFEI 1000521505Issued Jun 1, 2023Division of Human and Animal Food Operations East I
Source: FDA, published letter. FDA published this warning letter; View Letter opens FDA's copy. To check it, open FDA's record for this establishment, listed under FEI 1000521505.
Violations1
Issue DateJun 1, 2023
Product TypeDrugs
StatusClosed
Closeout LetterMay 30, 2024
Letter Details
Firm
A&Z Pharmaceutical, Inc.
Location
Emma Qingbo Li Xu
Chairwoman/CEO
A&Z Pharmaceutical, Inc.
180 Oser Ave., Suite 300
Hauppauge , NY 11788-3709
United States
emmaerwin@azpharmaceutical.com
FEI Number
1000521505
Country
United States
Issue Date
June 01, 2023
Issuing Office
Division of Human and Animal Food Operations East I
Product Type
Drugs
Status
Closed
Closeout Letter
May 30, 2024
Summary
A&Z Pharmaceutical, Inc. was cited for marketing Chewable Calcium 600MG with Vitamin D for Kids as an unapproved drug by making disease claims on their website and social media platforms, including claims that the product could prevent osteoporosis, slow bone loss, protect against gum disease, and reduce depression. These therapeutic claims violated the Federal Food, Drug, and Cosmetic Act by establishing the product's intended use as a drug without FDA approval or proper new drug application. The company was operating the product as a dietary supplement while simultaneously making claims that brought it under the legal definition of a drug under section 201(g)(1)(B) of the Act, constituting both a misbranding and unapproved new drug violation.
A&Z Pharmaceutical, Inc. FDA Warning Letter, June 1, 2023